<font color="blue">Lowering_1</font> <font color="blue">the_1</font> <font color="blue">triglyceride_3</font> <font color="blue">/_3</font> <font color="blue">high_3</font> <font color="blue">-_3</font> <font color="blue">density_3</font> <font color="blue">lipoprotein_3</font> <font color="blue">cholesterol_3</font> <font color="blue">ratio_3</font> is associated with the beneficial impact of <font color="blue">pioglitazone_1</font> <font color="blue">on_1</font> <font color="blue">progression_2</font> <font color="blue">of_2</font> <font color="blue">coronary_3</font> <font color="blue">atherosclerosis_3</font> in diabetic patients : insights from the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study . 
<br>
<br> OBJECTIVES The purpose of this study was to determine the <font color="blue">factors_1</font> associated with the favorable effect of <font color="blue">pioglitazone_1</font> <font color="blue">on_1</font> <font color="blue">atheroma_2</font> <font color="blue">progression_2</font> <font color="blue">._2</font> 
<br> BACKGROUND Diabetes mellitus is associated with accelerated <font color="blue">coronary_2</font> <font color="blue">atheroma_2</font> <font color="blue">progression_2</font> <font color="blue">._2</font> Pioglitazone slowed <font color="blue">progression_1</font> compared with glimepiride in this population . 
<br> METHODS In all , 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study . <font color="blue">Coronary_5</font> <font color="blue">atheroma_5</font> <font color="blue">progression_5</font> was evaluated by <font color="blue">serial_1</font> <font color="blue">intravascular_1</font> <font color="blue">ultrasound_1</font> <font color="blue">._1</font> <font color="blue">The_1</font> <font color="blue">relationship_2</font> <font color="blue">between_2</font> <font color="blue">changes_3</font> <font color="blue">in_3</font> <font color="blue">biochemical_3</font> <font color="blue">parameters_3</font> <font color="blue">,_3</font> <font color="blue">percent_3</font> <font color="blue">atheroma_3</font> <font color="blue">volume_3</font> <font color="blue">,_3</font> <font color="blue">and_3</font> <font color="blue">total_3</font> <font color="blue">atheroma_3</font> <font color="blue">volume_3</font> was investigated . 
<br> RESULTS Pioglitazone - treated patients demonstrated <font color="blue">greater_2</font> <font color="blue">increases_2</font> <font color="blue">in_2</font> <font color="blue">high_5</font> <font color="blue">-_5</font> <font color="blue">density_5</font> <font color="blue">lipoprotein_5</font> <font color="blue">cholesterol_5</font> <font color="blue">(_5</font> <font color="blue">HDL_5</font> <font color="blue">-_5</font> <font color="blue">C_5</font> <font color="blue">)_5</font> <font color="blue">and_4</font> <font color="blue">reductions_4</font> <font color="blue">in_4</font> <font color="blue">glycated_5</font> <font color="blue">hemoglobin_5</font> <font color="blue">,_5</font> <font color="blue">triglycerides_5</font> <font color="blue">,_5</font> <font color="blue">and_5</font> <font color="blue">C_5</font> <font color="blue">-_5</font> <font color="blue">reactive_5</font> <font color="blue">protein_5</font> <font color="blue">._5</font> Significant correlations were observed between <font color="blue">changes_3</font> <font color="blue">in_3</font> <font color="blue">percent_3</font> <font color="blue">atheroma_4</font> <font color="blue">volume_4</font> <font color="blue">and_3</font> <font color="blue">triglycerides_4</font> ( r = 0.15 , p = 0.04 ) , <font color="blue">triglyceride_3</font> <font color="blue">/_3</font> <font color="blue">HDL_3</font> <font color="blue">-_3</font> <font color="blue">C_3</font> <font color="blue">ratio_3</font> ( r = 0.16 , p = 0.03 ) , and <font color="blue">glycated_3</font> <font color="blue">hemoglobin_3</font> ( r = 0.16 , p = 0.03 ) with <font color="blue">pioglitazone_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">changes_3</font> <font color="blue">in_3</font> <font color="blue">low_4</font> <font color="blue">-_4</font> <font color="blue">density_4</font> <font color="blue">lipoprotein_5</font> <font color="blue">cholesterol_5</font> ( r = -0.15 , p = 0.05 ) , <font color="blue">apolipoprotein_5</font> <font color="blue">B_4</font> ( r = -0.16 , p = 0.04 ) , and <font color="blue">apolipoprotein_5</font> <font color="blue">A_2</font> <font color="blue">-_2</font> <font color="blue">I_2</font> ( r = -0.20 , p = 0.01 ) with glimepiride . <font color="blue">Substantial_1</font> <font color="blue">atheroma_2</font> <font color="blue">regression_2</font> <font color="blue">,_2</font> compared to <font color="blue">progression_1</font> <font color="blue">,_1</font> was associated with <font color="blue">greater_1</font> <font color="blue">relative_1</font> <font color="blue">increases_2</font> <font color="blue">in_2</font> <font color="blue">HDL_5</font> <font color="blue">-_5</font> <font color="blue">C_5</font> ( 14.2% vs. 7.8% , p = 0.04 ) , <font color="blue">relative_1</font> <font color="blue">decreases_1</font> <font color="blue">in_1</font> <font color="blue">triglycerides_5</font> ( -13.3% vs. -1.9% , p = 0.045 ) , <font color="blue">triglyceride_5</font> <font color="blue">/_5</font> <font color="blue">HDL_5</font> <font color="blue">-_5</font> <font color="blue">C_5</font> <font color="blue">ratio_4</font> ( -22.5 vs. -9.9% , p = 0.05 ) , and <font color="blue">decrease_1</font> <font color="blue">in_1</font> <font color="blue">glycated_4</font> <font color="blue">hemoglobin_4</font> ( -0.6% vs. -0.3% , p = 0.01 ) . Multivariable analysis revealed that pioglitazone - induced <font color="blue">effects_1</font> <font color="blue">on_1</font> <font color="blue">triglyceride_2</font> <font color="blue">/_2</font> <font color="blue">HDL_2</font> <font color="blue">-_2</font> <font color="blue">C_2</font> were associated with <font color="blue">changes_1</font> <font color="blue">in_1</font> <font color="blue">percent_2</font> <font color="blue">atheroma_3</font> <font color="blue">volume_2</font> <font color="blue">(_1</font> <font color="blue">p_1</font> = 0.03 ) and <font color="blue">total_2</font> <font color="blue">atheroma_3</font> <font color="blue">volume_2</font> ( p = 0.02 ) . 
<br> CONCLUSIONS Favorable <font color="blue">effects_1</font> of pioglitazone on the <font color="blue">triglyceride_3</font> <font color="blue">/_3</font> <font color="blue">HDL_3</font> <font color="blue">-_3</font> <font color="blue">C_3</font> <font color="blue">ratio_2</font> correlated with <font color="blue">delayed_1</font> <font color="blue">atheroma_4</font> <font color="blue">progression_4</font> <font color="blue">in_1</font> <font color="blue">diabetic_1</font> <font color="blue">patients_1</font> <font color="blue">._1</font> This finding highlights the potential importance of targeting <font color="blue">atherogenic_2</font> <font color="blue">dyslipidemia_2</font> in diabetic patients with <font color="blue">coronary_1</font> <font color="blue">artery_1</font> disease .